Yi Bi

Dr. Yi Bi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FXFeijie Xu
Feijie Xu
WLWenlong Li
Wenlong Li
WSWen Shuai
Wen Shuai
LYLimei Yang
Limei Yang
YBYi Bi
Yi Bi
JXJinyi Xu
Jinyi Xu

19 February 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WHWentao Huang
Wentao Huang
YWYingjie Wang
Yingjie Wang
SXSi Xu
Si Xu
HQHui Qiao
Hui Qiao
HCHaoran Cheng
Haoran Cheng
YBYi Bi
Yi Bi

15 October 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JLJunjun Long
Junjun Long
WJWentao Ji
Wentao Ji
DZDoudou Zhang
Doudou Zhang
YZYifei Zhu
Yifei Zhu
YBYi Bi
Yi Bi
Fusidic acid (FA) is a natural tetracyclic triterpene isolated from fungi, which is clinically used for systemic and local staphylococcal infections, including methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections. FA and its derivatives have been shown to possess a wide range of pharmacological activities, including antibacterial, antimalarial, antituberculosis, anticancer, tumor multidrug resistance reversal, anti-inflammation, antifungal, and antiviral activity in vivo and in vitro. The semisynthesis, structural modification and biological activities of FA derivatives have been extensively studied in recent years. This review summarized the biological activities and structure–activity relationship (SAR) of FA in the last two decades. This summary can prove useful information for drug exploration of FA derivatives.

9 November 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TYTao Yu
Tao Yu
HCHaoran Cheng
Haoran Cheng
XLXiaoli Li
Xiaoli Li
WHWentao Huang
Wentao Huang
HLHaixia Li
Haixia Li
LZLeiming Zhang
Leiming Zhang

1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JNJingxuan Ni
Jingxuan Ni
MGMengqi Guo
Mengqi Guo
YCYucheng Cao
Yucheng Cao
LLLei Lei
Lei Lei
KLKangli Liu
Kangli Liu
YBYi Bi
Yi Bi

7 April 2017 in Molecules
Verified
Journal Article
Open access
PDF file
YBYi Bi
Yi Bi
XLXian-Xuan Liu
Xian-Xuan Liu
HZHeng-Yuan Zhang
Heng-Yuan Zhang
XYXiao Yang
Xiao Yang
ZLZe-Yun Liu
Ze-Yun Liu
CYChun-Su Yuan
Chun-Su Yuan
Due to the rapidly growing bacterial antibiotic-resistance and the scarcity of novel agents in development, bacterial infection is still a global problem. Therefore, new types of antibacterial agents, which are effective both alone and in combination with traditional antibiotics, are urgently needed. In this paper, a series of antibacterial ocotillol-type C-24 epimers modified from natural 20(S)-protopanaxadiol were synthesized and evaluated for their antibacterial activity. According to the screening results of Gram-positive bacteria (B. subtilis 168 and MRSA USA300) and Gram-negative bacteria (P. aer PAO1 and A. baum ATCC19606) in vitro, the derivatives exhibited good antibacterial activity, particularly against Gram-positive bacteria with an minimum inhibitory concentrations (MIC) value of 2–16 µg/mL. The subsequent synergistic antibacterial assay showed that derivatives 5c and 6c enhanced the susceptibility of B. subtilis 168 and MRSA USA300 to chloramphenicol (CHL) and kanamycin (KAN) (FICI < 0.5). Our data showed that ocotillol-type derivatives with long-chain amino acid substituents at C-3 were good leads against antibiotic-resistant pathogens MRSA USA300, which could improve the ability of KAN and CHL to exhibit antibacterial activity at much lower concentrations with reduced toxicity.